Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19 | Lung Cancer | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

Educational Objective
To understand how oncologists can adjust their recommended dosage of pembrolizumab in a post-COVID-19 world
1 Credit CME

The coronavirus disease 2019 (COVID-19) pandemic has shocked the world and caused a period of both economic and medical catastrophe. Two major challenges face the world of medical oncology. Oncologists need to reconsider all of their clinical practices to decrease the risk of exposure of their patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oncologists also need to consider that the world has changed considerably in economic terms. Now, more than ever, we need to assess whether our recommended therapies will cause financial hardship, on both an individual and a societal level. In this article we propose a solution related to the dosing of pembrolizumab that will maintain therapeutic outcomes, decrease detrimental financial effects of treatment, and decrease exposure risk to SARS-CoV-2.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Daniel A. Goldstein, MD, Davidoff Center, Rabin Medical Center, Jabotinsky Street, Petach Tikvah, Israel (danielg3@tauex.tau.ac.il).

Published Online: May 27, 2020. doi:10.1001/jamaoncol.2020.2493

Conflict of Interest Disclosures: Dr Goldstein reported institutional research funding from Merck and personal fees from VIVIO Health. Dr Ratain reported personal fees from Aurobindo Pharma, Apotex, Ascentage Pharma, Teva Pharmaceutical Industries, Cyclacel Pharmaceuticals, Celltrion, Breckenridge Pharmaceutical, Par Pharmaceuticals, Roxane Laboratories, Aptevo Therapeutics, Accord Healthcare, Actavis, Amerigen Pharmaceuticals, Argentum Pharmaceuticals, BPI Labs, Belcher Pharmaceuticals, Dr Reddy’s Laboratories, Fresenius Kabi, Glenmark Pharmaceuticals, Hetero, Mylan, Sandoz, Pneuma Respiratory, and Shionogi; grants from AbbVie, Dicerna Pharmaceuticals, Genentech, and Xencor; and other fees from BeiGene; has a patent to US6395481B1 issued, licensed, and with royalties paid, a patent to EP1629111B1 issued, licensed, and with royalties paid, a patent to US8877723B2 issued, and a patent to US9617583B2 issued; and is director and treasurer of the Value in Cancer Care Consortium. No other disclosures were reported.

References
1.
Goldstein  DA , Gordon  N , Davidescu  M ,  et al.  A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer.   J Natl Cancer Inst. 2017;109(11). doi:10.1093/jnci/djx063PubMedGoogle Scholar
2.
Canadian Agency for Drugs and Technologies in Health. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs. Published online November 2019. Accessed May 19, 2020. https://www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf
3.
Goldstein  DA , Hirsch  A .  A policy that encourages wastage of expensive medications—the JW modifier.   JAMA Oncol. 2018;4(2):155-156. doi:10.1001/jamaoncol.2017.3997PubMedGoogle ScholarCrossref
4.
Lala  M , Li  M , Sinha  V , de Alwis  D , Chartash  E , Jain  L.   A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.   J Clin Oncol. 2018;36(15, supp):3062. doi:10.1200/JCO.2018.36.15_suppl.3062Google Scholar
5.
National Comprehensive Cancer Network. Coronavirus disease 2019 (COVID-19) resources for the cancer care community. Accessed May 19, 2020. https://www.nccn.org/covid-19/
6.
Elassaiss-Schaap  J , Rossenu  S , Lindauer  A ,  et al.  Using model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial.   CPT Pharmacometrics Syst Pharmacol. 2017;6(1):21-28. doi:10.1002/psp4.12132PubMedGoogle ScholarCrossref
7.
Merck announces fourth-quarter and full-year 2019 financial results. News release. Merck; February 5, 2020. Accessed May 19, 2020. https://s21.q4cdn.com/488056881/files/doc_financials/2019/q4/Merck-4QFY19-Earnings-News-Release.pdf
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close